Submit Manuscript

International Journal of Pharmacology

Year: 2014 | Volume: 10 | Issue: 5 | Page No.: 267-274
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 71

Authors

Mahir Kula

Gamze Tanriverdi

Ersoy Oksuz

Ayhan Bilir

Andleeb Shahzadi

Zeliha Yazici

Keywords

The present study was designed to investigate the combined effect of fotemustine, a nitrosureas antineoplastic agent along with simvastatin and/or dexamethasone on C6 glioblastoma. The C6 glioblastoma cells (1x106) were inoculated in rat brains. Ten days later, rats were treated with 10 mg kg-1 fotemustine, 3 mg kg-1 day-1 dexamethasone and 3 mg kg-1 day-1 simvastatin alone or with their combination. Monoclonal antibody Ki-67 was used to evaluate cell proliferation. The effects of these drug alone or in combination on fatty acid profile of C6 glioblastoma were determined using capillary gas chromatography. Dexamethasone±simvastatin decreased the tumor weight 36-46% (p = 0.001-0.029). The fotemustine+dexamethasone+simvastatin combination was more effective than the drugs given separately in inhibiting the growth of the tumor (33.9-58.5%, p = 0.000). In the fotemustine+dexamethasone+simvastatin group, the total fatty acid amount was high compared with control tumors, whereas low in the fotemustine+simvastatin group (31.95±1.91 and 16.11±1.96 μg mg-1, p = 0.021). The number of Ki-67 positive cell decreased compared with control tumors by drug therapy except dexamethasone alone. The decrease was greatest in the treatment with fotemustine+dexamethasone+simvastatin (26.5-51.8%, p = 0.000-0.020). These data show that, fotemustine+dexamethasone+simvastatin combination is more effective than fotemustine alone on inhibition of cell proliferation and tumor progression.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *